Volume 5, Number 1—February 1999
Perspective
The Economic Impact of Staphylococcus aureus Infection in New York City Hospitals
Table 6
Source of infection | Incidence | Direct medical cost |
||||
---|---|---|---|---|---|---|
Total ($M) | Per patient ($) | Deaths |
||||
Total | (%) | |||||
Nosocomial | 6,300 | 181.0 | 28,800 | 640 | 10 | |
Community | 7,250 | 254.5 | 5,300 | 760 | 11 | |
Pneumonia | 1,500 | 51.7 | 34,900 | 380 | 25 | |
Non-pneumonia | 5,750 | 202.8 | 35,400 | 380 | 7 | |
MRSAa | 2,780 | 94.5 | 34,000 | 590 | 21 | |
MSSAb | 10,770 | 339.4 | 31,500 | 810 | 8 |
aMethicillin-resistant strains of S. aureus.
bMethicillin-sensitive strains of S. aureus.
Page created: December 07, 2010
Page updated: December 07, 2010
Page reviewed: December 07, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.